FDA Requests Public Comment on Proposed Collection of Information for Postmarketing Adverse Experience Reporting and Recordkeeping

Summary

The Food and Drug Administration is requesting public comment on a proposed collection of information for postmarketing adverse experience reporting and recordkeeping for drug and biological products, which has been submitted to the Office of Management and Budget for review and clearance under the Paperwork Reduction Act of 1995.